Dimerix Limited

10 articles about Dimerix Limited

• DIMERIX’s DMX-200 Posts Strong Results in Kidney Disease Trial

  7/29/2020

  Melbourne-based, clinical-stage biopharmaceutical company Dimerix has reported excellent results from the clinical trial of its drug candidate DMX-200, which is aimed at a rare kidney disease called focal segmental glomerulosclerosis, or FSGS.

• Dimerix Limited Quarterly Review - Q2 FY2018

  1/29/2018

  Dimerix Limited together with a review of activities and developments from the quarter.

• Dimerix Bioscience Pty Ltd Release: Recorded Interview With CEO and Rights Issue Reminder

  1/16/2018

  Dimerix is pleased to provide shareholders with access to a recorded interview where CEO, Kathy Harrison discusses the recent dose optimisation ASX announcement for DMX-200.

• Dimerix and Proteomics Partner to Improve Treatment of Chronic Kidney Disease

  12/14/2017

  Proteomics International and Dimerix will evaluate the performance of PromarkerD alongside DMX-200 in early phase clinical trials for chronic kidney disease.

• Dimerix to Present at the 2nd World Congress for Clinical Trials in Diabetes

  11/27/2017

  The World Congress for Clinical Trials in Diabetes will bring together over 300 representatives from regulatory agencies and the pharmaceutical industry across a range of disciplines including endocrinologists, cardiologists, neurologists and nephrologists.

• Dimerix Presents Detailed Subgroup Analysis From DMX-200 Phase IIa Trial in Chronic Kidney Disease Showing Compelling Efficacy Signals in Diabetic Nephropathy Patients

  11/2/2017

  Five of the 6 patient responder sub-group (83%) had a primary diagnosis of diabetic nephropathy and 1 of the 6 responders (17%) had a primary diagnosis of IgA nephropathy.

• Dimerix Receives Ethics Committee Approval in Australia for Pharmacokinetic Trial of New Extended Release Formulation

  10/24/2017

  Dimerix Limited, is pleased to announce that it has received ethics committee approval for a study in healthy volunteers to determine the pharmacokinetic properties of the novel extended release propagermanium tablet to be used in the Company's DMX-200 Phase 2b trial in Chronic Kidney Disease.

• Dimerix Limited Announces DMX--200 Tablet Manufacture And Human Pharmacokinetic Study Timeline

  9/5/2017

• Dimerix Limited To Present Analysis Of DMX-200 Phase IIa Clinical Trial In Chronic Kidney Disease At The American Society of Nephrology (ASN) Annual Kidney Week 2017

  8/16/2017

• Dimerix Limited Reports Positive Results From Phase IIa Trial Of DMX-200 In Chronic Kidney Disease

  7/12/2017